- Home
- XTNT vs IFRX Comparison
XTNT vs IFRX Comparison
Compare XTNT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- IFRX
- Stock Information
- Founded
- XTNT N/A
- IFRX 2007
- Country
- XTNT United States
- IFRX Germany
- Employees
- XTNT N/A
- IFRX N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- XTNT Health Care
- IFRX Health Care
- Exchange
- XTNT Nasdaq
- IFRX Nasdaq
- Market Cap
- XTNT 60.9M
- IFRX 53.5M
- IPO Year
- XTNT N/A
- IFRX 2017
- Fundamental
- Price
- XTNT $0.63
- IFRX $0.86
- Analyst Decision
- XTNT
- IFRX Strong Buy
- Analyst Count
- XTNT 0
- IFRX 4
- Target Price
- XTNT N/A
- IFRX $7.75
- AVG Volume (30 Days)
- XTNT 69.9K
- IFRX 210.6K
- Earning Date
- XTNT 08-12-2025
- IFRX 08-07-2025
- Dividend Yield
- XTNT N/A
- IFRX N/A
- EPS Growth
- XTNT N/A
- IFRX N/A
- EPS
- XTNT N/A
- IFRX N/A
- Revenue
- XTNT $127,766,000.00
- IFRX $191,224.00
- Revenue This Year
- XTNT $12.68
- IFRX N/A
- Revenue Next Year
- XTNT $5.40
- IFRX $1,276.37
- P/E Ratio
- XTNT N/A
- IFRX N/A
- Revenue Growth
- XTNT 15.16
- IFRX 54.36
- 52 Week Low
- XTNT $0.33
- IFRX $0.71
- 52 Week High
- XTNT $0.78
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- XTNT 51.87
- IFRX 50.72
- Support Level
- XTNT $0.57
- IFRX $0.78
- Resistance Level
- XTNT $0.70
- IFRX $0.86
- Average True Range (ATR)
- XTNT 0.05
- IFRX 0.07
- MACD
- XTNT 0.01
- IFRX 0.00
- Stochastic Oscillator
- XTNT 57.31
- IFRX 58.33
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.